Patients who received Intercept Pharmaceuticals Inc.'s experimental liver-disease drug in a clinical trial experienced more abnormal cholesterol levels than those taking a placebo, in addition to improvements in their liver health, according to the National Institutes of Health.. Patients taking the drug had "disproportionate lipid abnormalities"—including worsened cholesterol levels—compared with patients who received a placebo in the 283-person study, according to the NIH. The NIH's National Institute of Diabetes...
  